This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting and is pleased to share the following Emerging Science abstracts, which qualified by having key aspects of research conducted after the October 11, 2022, abstract submission deadline. They are new and of sufficient scientific importance to warrant expedited presentation and publication.
Abstracts were featured in data blitz format during the Emerging Science sessions at the Annual Meeting in Boston. There were also 2 abstracts presented as part of the Clinical Trials Plenary Session.
UB-313, an Investigational CGRP Vaccine for the Prevention of Migraine
Jean-Cosme Dodart, Hui-jing Yu, Justin Boyd, Eric Hsieh, Hanxin Lu, Shixia Wang, Martina Ramos, Alanis Sun, Matthew Longo, Madeline Vroom, Shuang Ding, Brett Thibodeaux, Jeanne Brooks, Jaya Sahni, Jonathan Wiggins, Dario Mirski
Objective
The aim of this study was to obtain preclinical characterization of UB-313 in support of clinical development.
Background
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) have demonstrated efficacy for the prevention of migraine. UB-313, a vaccine designed to stimulate the production of endogenous antibodies against CGRP, might provide an attractive new option to prevent migraine.
Design/Methods
Immunogenicity studies were conducted in rodents and monkeys. Vaccine-induced serum antibodies were characterized for their binding and functional properties. Efficacy was assessed in a rat capsaicin model, and toxicity was evaluated in a repeat-dose good laboratory practice study.
Results
Studies in rodents and monkeys demonstrated that immunization with UB-313 induces robust anti-CGRP antibodies across species. Affinity-purified antibodies from immunized animals were shown to bind human CGRP with high affinity (KD in the low pM range) and demonstrated a dose-dependent functional inhibition of CGRP (EC50 in the low nM range) in cell-based assays, indicating antibody properties comparable with marketed monoclonal antibodies. Off-target analyses indicated very high specificity of the anti-CGRP antibodies for human CGRP. It is of interest that antibodies induced by UB-313 demonstrate a stronger …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- UB-313, an Investigational CGRP Vaccine for the Prevention of Migraine
- Expansion of an Intronic FGF14 GAA Short Tandem Repeat in Late-Onset Cerebellar Ataxia
- Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
- Peripheral Blood Gene Expression Transcriptional Profiling Predicts Disease Progression in Primary Progressive Multiple Sclerosis
- Efficacy and Safety of Continuous Subcutaneous ND0612 Infusion Compared With Oral Immediate-Release Levodopa-Carbidopa in Patients With Parkinson Disease and Motor Fluctuations: Results From the Phase 3 Multicenter, Randomized, Double-blind, Double-Dummy BouNDless Trial
- The Effect of Catheter Ablation on Cognitive Outcomes in Elderly Patients With Atrial Fibrillation: SAGE-AF
- Mitochondrial Dysfunction in Neuron-Derived Extracellular Vesicles and Brain Tissues of FXTAS Patients
- RELIEF-PHN1: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial of LX9211 in the Treatment of Postherpetic Neuralgia Pain
- Teriflunomide (Aubagio) Extends the Time to Multiple Sclerosis in Radiologically Isolated Syndrome: The TERIS Study
- Continuous Delivery of Levodopa/Carbidopa Using the Intra-oral DopaFuse System: A Safety, Tolerability, Pharmacokinetics, and Efficacy Trial
- Eplontersen in Hereditary ATTR-Polyneuropathy: Week 66 Final Analysis of the Phase 3 NEURO-TTRansform Study
- Interim Results From the NEXUS Open-Label Registration Study on the Safety and Efficacy of Leriglitazone in the Treatment of Childhood Cerebral Adrenoleukodystrophy
- Deoxycytidine/Deoxythymidine Combination Therapy Safety and Efficacy in Treatment of POLG-Related Disorders: Results After 6 Months of Treatment
- MEGAbIT: The Role of Magnetoencephalography in Assessment and Diagnosis in Mild Traumatic Brain Injury
- First-in-Human Trial of NRTX-1001 GABAergic Interneuron Cell Therapy for Treatment of Focal Epilepsy: Emerging Clinical Trial Results
- MOG-IgA Characterizes a Subgroup of Patients With CNS Demyelination
- A Randomized Trial of Endovascular Thrombectomy vs Medical Management For Ischemic Stroke With a Large Core Infarct on Non-contrast CT or Perfusion Imaging
- Holter of Movement Provides the First Digital Outcome Qualified by a Regulatory Agency
- Topline Results of the PROOF-HD Pivotal Phase 3 Trial: PRidopidine's Outcome On Function in Huntington Disease
- ACHIEVE Trial: A Randomized, Placebo-Controlled, Multiple Ascending Dose Study of DYNE-101 in Individuals With Myotonic Dystrophy Type 1
- Effects of EDG-5506, a Fast Myosin Modulator, on Proteomic Biomarker Profile of Muscle Damage in Adults With Becker Muscular Dystrophy
- Info & Disclosures
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard